Urticarial vasculitis is a rare inflammation of the blood vessels which results in clinical manifestations resembling urticaria with the addition of wheals, there remain no direct treatment options and management involves antihistamines, NSAIDS and ibuprofen to treat the cutaneous manifestations. We were delighted to speak to Dr. Pavel Kolkhir (Charité-Universitätsmedizin Berlin, Berlin, Germany) around the […]

Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]

The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]

Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]

Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]

Juvenile idiopathic arthritis awareness week (JIAAW) is taking place between 3-7 July to raise awareness and dispel misconceptions around JIA, this year’s theme is #BustingJIAMyths, you can take part by entering the ‘JIA Mythbuster’ quiz and joining the conversation on social media using #BustingJIAMyths  and #JIAAW2023. touchIMMUNOLOGY were delighted to talk with CEO Clare Jacklin and support […]

The phase 3 LIBERTY-EoE-TREET study (NCT03633617) investigated the efficacy and safety of dupilumab in eosinophilic esophagitis. In this interview we spoke with Dr. Margaret Collins (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA) around her analysis of the phase 3 study looking at the eosinophil count and histologic score at 24 weeks of dupilumab 300 […]

Dupilumab, a fully human monoclonal antibody that works by blocking IL-4Rα, is currently approved for the treatment of eosinophilic esophagitis (EoE) in the USA and EU. It was a pleasure to talk with Dr. Margaret Collins (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA) around the mechanism of action of dupilumab and the impact its […]

touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on the potential of CD19-targeted CAR-T cell transfer for systemic sclerosis. The abstract ‘Effects of B cell depletion by […]